Colonic schwannomas and gastrointestinal stromal tumors (GISTs) are rare types of tumors that can occur in the gastrointestinal tract. Schwannomas originate from Schwann cells, which are ...
Gastrointestinal stromal tumors (GIST) are rare mesenchymal tumors and were among the first solid tumor types for which such a novel treatment (in this case imatinib) became available. The ...
Gastrointestinal stromal tumors (GISTs) are the most common type of mesenchymal tumors found in the gastrointestinal tract of dogs and are characterized by specific cellular markers. These tumors ...
British pharmaceutical company GSK on Monday said it had agreed to buy a US company that specializes in the treatment of rare ...
For patients with gastrointestinal stromal tumors with liver metastases, treatment with surgery and chemotherapy has been found to have survival benefits.
Treatment with bezuclastinib plus Sutent led to safe and efficacious outcomes versus Sutent treatment alone in gastrointestinal stromal tumors.
UK pharma major GSK is to acquire IDRx, a Boston, USA-based, clinical-stage biopharma developing precision therapeutics for ...
Hosted on MSN18d
GSK is said to be nearing $1B deal to acquire U.S. biotech IDRxA clinical-stage biotech founded in 2022 ... Its initial product candidate, IDRX-42, targets gastrointestinal stromal tumor (GIST), a GIT cancer that affects an estimated 4,000–6,000 Americans ...
(RTTNews) - British drug maker GSK plc (GSK.L, GSK) Monday announced that it has signed an agreement to acquire IDRx, a Boston-based, clinical-stage biopharmaceutical company, for up to $1.15 billion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback